Journal of atherosclerosis and thrombosis最新文献_第5页

Gout, Uric Acid, and Coronary Artery Disease. 痛风、尿酸和冠状动脉疾病。

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-30 DOI: 10.5551/jat.RV22043

Takuya Nakahashi, Hayato Tada, Kenji Sakata, Masayuki Takamura

{"title":"Gout, Uric Acid, and Coronary Artery Disease.","authors":"Takuya Nakahashi, Hayato Tada, Kenji Sakata, Masayuki Takamura","doi":"10.5551/jat.RV22043","DOIUrl":"https://doi.org/10.5551/jat.RV22043","url":null,"abstract":"Hyperuricemia, the biochemical precursor to gout, is usually defined as the theoretical limit of solubility of serum uric acid (UA) of ＞7.0 mg/dL. Hyperuricemia is closely associated with hypertension, diabetes mellitus, and dyslipidemia, which are well known to be related to risk factors for coronary artery disease (CAD). Furthermore, hyperuricemia has been associated with increased mortality in both the general population and individuals with cardiovascular diseases. Elevated UA in patients with CAD is accompanied by surrogate markers of atherosclerosis, including C-reactive protein, platelet activation, and endothelial dysfunction, which can contribute to possible pathogenic links between hyperuricemia and subsequent adverse cardiovascular events. Similarly, patients with gout have higher rates of cardiovascular diseases than those without it, independent of traditional cardiovascular risk factors. Gout is a disease with variable levels of inflammation, driven by deposition of monosodium urate (MSU) crystals. Recent imaging technology has revealed that deposition of MSU crystals can occur in the coronary arteries as well as the joints. However, current evidence does not support the efficacy of urate-lowering therapy on reducing cardiovascular events in patients with hyperuricemia; therefore, identifying individuals who may benefit from a sustained decrease in UA is crucial. We herein review the current understanding and future perspectives for management of hyperuricemia as a residual risk in patients with CAD.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intracranial Artery Calcification Relates to Brain Damage and Clinical Outcomes in Patients Receiving Intravenous Thrombolysis. 颅内动脉钙化与静脉溶栓患者脑损伤及临床预后有关。

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-26 DOI: 10.5551/jat.65700

Jiaxin Liu, Xue Chen, Yuchen Liang, Dehong Liu, Xinyue Cheng, Yang Qu, Hongwei Zhou, Zhen-Ni Guo

{"title":"Intracranial Artery Calcification Relates to Brain Damage and Clinical Outcomes in Patients Receiving Intravenous Thrombolysis.","authors":"Jiaxin Liu, Xue Chen, Yuchen Liang, Dehong Liu, Xinyue Cheng, Yang Qu, Hongwei Zhou, Zhen-Ni Guo","doi":"10.5551/jat.65700","DOIUrl":"https://doi.org/10.5551/jat.65700","url":null,"abstract":"Aim: Intracranial artery calcification (IAC) in patients with acute ischemic stroke may cause cerebral hemodynamic injury and aggravate ischemia-reperfusion injury. However, its relationship with brain damage and clinical outcomes has not yet been fully explored.Methods: Patients with acute anterior circulation ischemic stroke who underwent intravenous thrombolysis (IVT) were enrolled. Intracranial artery calcification (IAC) was assessed using the IAC volume and number of calcified vessels (NCV) on pre-IVT computed tomography. Outcomes included the degree of brain injury at 24 h post-IVT, measured by serum glial fibrillary acidic protein (GFAP) levels, final infarct volumes, intracranial hemorrhaging within 24 h of IVT, and a poor prognosis at 90 days (modified Rankin Scale ＞2). A multivariate regression analysis was conducted to evaluate the associations between IAC parameters and clinical outcomes.Results: A total of 348 patients were enrolled in the study, of whom 273 (78.4%) had IAC. Patients were divided into four quartile groups (Q1, Q2, Q3, and Q4) based on the total IAC volume. The fourth quartile (Q4), which included patients with the highest IAC volume, was independently associated with elevated GFAP levels (odds ratio [OR] = 2.449, 95% confidence interval [CI], 1.057-5.673; P = 0.037). The second quartile (Q2) was independently associated with final infarct volume (β:0.483, 95% CI:0.014-0.952, P = 0.044). In addition, NCV was independently correlated with increased GFAP levels (OR = 1.265, 95% CI:1.010-1.584, P = 0.040) and a poor prognosis (OR = 1.270, 95% CI: 1.008-1.600, P = 0.043).Conclusion: IAC was independently associated with the degree of brain injury, final infarct volume, and prognosis in patients after IVT.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis. 替鲁司特代谢物增强ABCA1和ABCG1表达和胆固醇外流：动脉粥样硬化的潜在治疗策略

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-22 DOI: 10.5551/jat.65669

Huicheng Qi, Masatsune Ogura, Kazuko Matsuda, Takashi Miida

{"title":"Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis.","authors":"Huicheng Qi, Masatsune Ogura, Kazuko Matsuda, Takashi Miida","doi":"10.5551/jat.65669","DOIUrl":"https://doi.org/10.5551/jat.65669","url":null,"abstract":"Aims: MN-001 (tipelukast), a compound with lipid-modulating and anti-inflammatory properties, and its active metabolite MN-002, have been suggested to influence cholesterol metabolism. This study aimed to investigate whether MN-001 and MN-002 enhance cholesterol efflux via ABCA1 and ABCG1, thereby reducing foam cell formation. We also evaluated cholesterol efflux capacity in patients with diabetes before and after MN-001 administration.Methods: Cholesterol efflux was assessed in THP-1 macrophages treated with MN-001 and MN-002 in the presence of ApoA-I or HDL. ABCA1 and ABCG1 expression were evaluated using western blot and qPCR analyses. A 12-week observational study in patients with diabetes evaluated the cholesterol efflux capacity using ApoB-depleted serum and radiolabeled J774.1 macrophages. Molecular docking simulations were conducted to explore MN-002 binding affinities, aiming to identify potential target proteins and elucidate the molecular mechanisms underlying their effects on cholesterol metabolism.Results: MN-002 enhanced ABCA1-mediated cholesterol efflux and upregulated ABCA1 expression independently of PKA. It also increased ABCG1 expression; however, neither MN-001 nor MN-002 influenced HDL-mediated efflux. MN-001 showed no significant improvement in cholesterol efflux capacity (p = 0.6507) in patients with diabetes. Molecular docking simulations indicated that MN-002 may bind to PPAR-alpha, suggesting a potential mechanism for its effects.Conclusion: MN-002 offers a novel therapeutic approach for atherosclerosis by upregulating ABCA1 and ABCG1 expression and enhancing ApoA-I-mediated cholesterol efflux. Further studies are required to clarify the underlying mechanisms and assess their clinical potential in atherosclerosis and metabolic disorders.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short-Term Treatment for Immune-Mediated Acquired Lecithin-Cholesterol Acyltransferase Deficiency Restores the High-Density Lipoprotein Function: A Case Report. 短期治疗免疫介导的获得性卵磷脂-胆固醇酰基转移酶缺乏症可恢复高密度脂蛋白功能：1例报告

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-22 DOI: 10.5551/jat.65784

Tomohiro Komatsu, Satomi Abe, Masayuki Kuroda, Yasuhiro Endo, Kei Sasaki, Takafumi Nishida, Manami Teramoto, Junko Arakawa, Koji Kuwata, Toshihiko Imakiire, Yoshiro Maezawa, Koutaro Yokote, Yoshinari Uehara, Katsunori Ikewaki

{"title":"Short-Term Treatment for Immune-Mediated Acquired Lecithin-Cholesterol Acyltransferase Deficiency Restores the High-Density Lipoprotein Function: A Case Report.","authors":"Tomohiro Komatsu, Satomi Abe, Masayuki Kuroda, Yasuhiro Endo, Kei Sasaki, Takafumi Nishida, Manami Teramoto, Junko Arakawa, Koji Kuwata, Toshihiko Imakiire, Yoshiro Maezawa, Koutaro Yokote, Yoshinari Uehara, Katsunori Ikewaki","doi":"10.5551/jat.65784","DOIUrl":"https://doi.org/10.5551/jat.65784","url":null,"abstract":"Familial lecithin-cholesterol acyltransferase (LCAT) deficiency with a primary LCAT gene mutation results in various conditions, including corneal opacity, anemia, kidney disease, and low high-density lipoprotein (HDL) levels. In recent years, secondary LCAT deficiency with nearly identical symptoms has been identified as a rare case of immune-mediated acquired LCAT deficiency caused by LCAT autoantibodies. In limited cases, prednisolone treatment is required for severe conditions and has been shown to favorably modulate LCAT autoantibodies and restore LCAT activity, resulting in improved HDL-cholesterol (HDL-C) levels, renal dysfunction, and other complications. However, there is little detailed information regarding LCAT activity, lipid changes, and renal dysfunction after the initiation of prednisorone treatment. In the present study, in addition to the effects on LCAT activity, lipids, and proteinuria, we for the first time monitored the HDL cholesterol efflux capacity (CEC), an important anti-atherosclerotic HDL function, during the first month of treatment in a patient with this disease. We found that the LCAT activity, HDL-C concentration, and HDL CEC increased from undetectable or low values to normal ranges during this period, as did proteinuria. Specifically, the HDL CEC and LCAT activity recovered faster than the HDL-C levels. Based on these findings, the effects of prednisolone treatment on LCAT and HDL CEC activities prior to HDL-C levels suggest that normal HDL-C levels may not be essential as a treatment target in immune-mediated acquired LCAT deficiency patients who require treatment.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting the Role of Interleukin-6 in Predicting Stroke and Cardiovascular Events. 白细胞介素-6在脑卒中和心血管事件预测中的作用

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-22 DOI: 10.5551/jat.ED288

Kaori Miwa

引用次数: 0

Apolipoprotein E-Containing High-Density Lipoprotein is Independently Associated with Atherosclerotic Plaque Progression. 载脂蛋白e -含高密度脂蛋白与动脉粥样硬化斑块进展独立相关。

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-19 DOI: 10.5551/jat.65441

Pinfei Ni, Jiangtao Li, Youling Duan, Piaopiao Hu, Qiuju Deng, Yongchen Hao, Zhao Yang, Lizhen Han, Yue Qi, Jing Liu

{"title":"Apolipoprotein E-Containing High-Density Lipoprotein is Independently Associated with Atherosclerotic Plaque Progression.","authors":"Pinfei Ni, Jiangtao Li, Youling Duan, Piaopiao Hu, Qiuju Deng, Yongchen Hao, Zhao Yang, Lizhen Han, Yue Qi, Jing Liu","doi":"10.5551/jat.65441","DOIUrl":"https://doi.org/10.5551/jat.65441","url":null,"abstract":"Aim: Mounting evidence suggests apolipoprotein E-containing high-density lipoprotein cholesterol (APOE-HDLC) as an indicator of the anti-atherogenic function of HDLC, but data are lacking on whether or not APOE-HDLC is involved in the development of atherosclerosis in humans. This study was performed to explore whether or not APOE-HDLC is associated with atherosclerotic plaque progression in humans.Methods: Among 823 participants 45 to 74 years old who were free of cardiovascular disease, we assessed nuclear magnetic resonance spectroscopy-measured HDL particle concentrations, APOE-HDLC levels and HDLC levels at baseline, and performed carotid ultrasound measurements in surveys conducted in 2002 and again in 2007 after a 5-year interval. The ratio of APOE-HDLC to total HDLC (APOE-HDLC/HDLC ratio) was calculated to assess the relative proportion of APOE-HDLC in total HDLC, given the strong correlation between them.Results: The baseline APOE-HDLC/HDLC ratio was significantly associated with the risk of 5-year plaque progression (relative risk [RR] = 0.71; 95% confidence interval [CI] = 0.53-0.95), which is independent of the ratio of HDLC to the HDL particle number (HDLC/P ratio). In particular, participants with an HDLC/P ratio ≥ 44.8 (denoted very high level of cholesterol content per HDLP, a marker of dysfunctional HDL) had a 36% reduced 5-year plaque progression risk (RR = 0.64; 95% CI = 0.43-0.97) if combined with the highest APOE-HDLC/HDLC ratio, as compared with the lowest APOE-HDLC/HDLC ratio.Conclusions: These results highlight the potential utility of APOE-containing HDL as a candidate emerging biomarker for the anti-atherosclerotic function of HDL particles.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are Per- and Polyfluoroalkyl Substances Forever Risk Factors for Cardiovascular Disease? 全氟和多氟烷基物质永远是心血管疾病的危险因素吗？

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-13 DOI: 10.5551/jat.ED287

Takehiro Michikawa

引用次数: 0

Safe Continuation of Apheresis during Pregnancy using the Double-Filtration Plasmapheresis Thermo Mode in a Pregnant Female with Familial Hypercholesterolemia: A Case Report. 妊娠期使用双滤过血浆分离热模式安全继续血浆分离1例家族性高胆固醇血症孕妇报告

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-13 DOI: 10.5551/jat.65360

Yoshimasa Sakurabu, Haruhito A Uchida, Yuka Okuyama, Eriko Eto, Kanako Takasugi, Tomohiko Asakawa, Katsuyoshi Katayama, Shugo Okamoto, Yasuhiro Onishi, Natsumi Matsuoka-Uchiyama, Chihiro Fujihara, Keiko Tanaka, Hidemi Takeuchi, Ryoko Umebayashi, Katsuyuki Tanabe, Jun Wada

{"title":"Safe Continuation of Apheresis during Pregnancy using the Double-Filtration Plasmapheresis Thermo Mode in a Pregnant Female with Familial Hypercholesterolemia: A Case Report.","authors":"Yoshimasa Sakurabu, Haruhito A Uchida, Yuka Okuyama, Eriko Eto, Kanako Takasugi, Tomohiko Asakawa, Katsuyoshi Katayama, Shugo Okamoto, Yasuhiro Onishi, Natsumi Matsuoka-Uchiyama, Chihiro Fujihara, Keiko Tanaka, Hidemi Takeuchi, Ryoko Umebayashi, Katsuyuki Tanabe, Jun Wada","doi":"10.5551/jat.65360","DOIUrl":"https://doi.org/10.5551/jat.65360","url":null,"abstract":"Familial hypercholesterolemia (FH) is an inherited disorder characterized by elevated LDL cholesterol levels and an increased risk of early-onset atherosclerotic cardiovascular disease. In pregnant female with FH, apheresis is the preferred treatment because standard therapeutic agents such as statins are contraindicated during pregnancy. LDL adsorption therapy is commonly used; however, after 27 weeks of gestation, it is often switched to dual filtration plasma exchange (DFPP) due to the significant drop in blood pressure caused by bradykinin production. However, DFPP has limited ability to adapt to the increase in circulating plasma volume associated with pregnancy. Here we discuss the case of a 32-year-old female with homozygous FH who underwent different apheresis strategies during her pregnancies. In her first pregnancy, she continued LDL adsorption therapy using DFPP but ultimately delivered a small-for-gestational-age infant via cesarean section. For her second pregnancy, double-filtration plasmapheresis thermo mode, DF-thermo, was introduced to mitigate the limitations of DFPP and LDL adsorption therapies, such as hypotension during apheresis and albumin loss. By minimizing these complications, DF-thermo allowed for a successful delivery without compromising fetal growth.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144846601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis. 他汀类药物和PCSK9抑制剂在可能有家族性高胆固醇血症和冠状动脉狭窄的孕妇中的联合应用

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-09 DOI: 10.5551/jat.65696

Yusaku Shimizu, Tae Yokouchi-Konishi, Chizuko Aoki-Kamiya, Mai Temukai, Kotaro Hizuka, Masami Sawada, Aiko Kakigano, Naoko Iwanaga, Takeshi Kanagawa, Kota Murai, Hisashi Makino, Jun Yoshimatsu

{"title":"Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis.","authors":"Yusaku Shimizu, Tae Yokouchi-Konishi, Chizuko Aoki-Kamiya, Mai Temukai, Kotaro Hizuka, Masami Sawada, Aiko Kakigano, Naoko Iwanaga, Takeshi Kanagawa, Kota Murai, Hisashi Makino, Jun Yoshimatsu","doi":"10.5551/jat.65696","DOIUrl":"https://doi.org/10.5551/jat.65696","url":null,"abstract":"Although the risk of acute coronary syndrome increases during pregnancy and the postpartum period compared to the non-pregnant state, dyslipidemia-one of the key risk factors for atherosclerotic cardiovascular disease-is often undertreated in this population. Several lipid-lowering medications, including statin, have not been used due to concerns about their impact on the fetus. Herein, we report a pregnant woman with possible familial hypercholesterolemia (FH) and coronary artery stenosis, whose low-density lipoprotein cholesterol (LDL-C) level was managed by a combination of statin and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for the secondary prevention of coronary artery disease.A 37-year-old pregnant woman with dyslipidemia was found to have severe coronary artery stenosis. She was suspected of having FH, and her lipid control was initiated with the goal of lowering LDL-C levels to ＜100 mg/dL. Although ezetimibe and colestimide were administered at 14 weeks, the target LDL-C level was not achieved. Thus, treatment with pravastatin was started at 23 weeks and evolocumab at 32 weeks of gestation. With the combination of pravastatin and evolocumab, her LDL-C levels decreased to 67 mg/dL after 35 weeks of gestation. The patient delivered vaginally at 37 weeks of gestation without any cardiac events, and her baby did not present with any abnormalities. In conclusion, the combined use of statin and PCSK9 inhibitor could effectively manage LDL-C levels, and it might be a safe option during pregnancy. Nevertheless, further research is required to assess the safety and efficacy of this combination therapy during pregnancy.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Von Willebrand Factor Multimers in Aortic Stenosis Surgery: Dynamics and Disease Correlation. 主动脉狭窄手术中的血管性血友病因子多聚体：动力学和疾病相关性。

IF 2.8 2区医学

Journal of atherosclerosis and thrombosis Pub Date : 2025-08-08 DOI: 10.5551/jat.65800

Shuji Tachioka, Hideaki Kanda, Munekazu Yamakuchi, Sadayuki Higashi, Misako Suzuki, Drew N Maywar, Kenji Toyokawa, Kosuke Mukaihara, Kazuhisa Matsumoto, Hisanori Horiuchi, Teruto Hashiguchi, Yoshiharu Soga

{"title":"Von Willebrand Factor Multimers in Aortic Stenosis Surgery: Dynamics and Disease Correlation.","authors":"Shuji Tachioka, Hideaki Kanda, Munekazu Yamakuchi, Sadayuki Higashi, Misako Suzuki, Drew N Maywar, Kenji Toyokawa, Kosuke Mukaihara, Kazuhisa Matsumoto, Hisanori Horiuchi, Teruto Hashiguchi, Yoshiharu Soga","doi":"10.5551/jat.65800","DOIUrl":"https://doi.org/10.5551/jat.65800","url":null,"abstract":"Aim: The preoperative to early remote postoperative von Willebrand factor (VWF) large multimer index (LMI) in patients with aortic stenosis (AS) remains unclear. Assessment of LMI changes may be better understood if other valvular diseases are integrated. However, this association requires further investigation.Methods: A quantitative time-course assessment of the VWF, including LMI, was performed in 23 patients with AS who underwent aortic valve replacement. The proposed total valve score was used to study the correlation between the LMI and valvular diseases, including diseases other than AS.Results: The postoperative VWF LMI was significantly higher; this increase was sustained across nine measurements up to one year postoperatively. The total valve score showed a moderate negative correlation with the VWF LMI (Spearman correlation coefficient rs = -0.5483, p = 0.0068), demonstrating a stronger negative correlation and a lower p-value than the peak flow velocity and mean pressure gradient.Conclusions: Improved VWF LMI was maintained one year after AS surgery and correlated better with echocardiographic severity when considering other valvular diseases than AS severity alone. VWF LMI may indicate overall cardiac shear stress and treatment effectiveness in early remote stages.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0